Karuna Therapeutics – Follow-up on Trial Evaluating KarXT in Schizophrenia
Returning guest, Dr. Andrew Miller, Founder and Chief Operating Officer of Karuna Therapeutics and lead inventor of the company’s lead investigational therapy, KarXT (xanomeline-trospium), discusses positive topline results from its Phase 3 EMERGENT-2 trial evaluating KarXT in adults with schizophrenia. He talks about what these data may mean for those living with or treating schizophrenia, the potential for KarXT to change how we approach the treatment of serious mental illnesses, and the potential for progress with greater education and understanding of mental disorders.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Therapy?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Andrew Miller, Founder and Chief Operating Officer of Karuna Therapeutics and lead inventor of the company’s lead investigational therapy, KarXT (xanomeline-trospium), discusses…
- Key Point: He talks about what these data may mean for those living with or treating schizophrenia, the potential for KarXT to change how we approach the treatment of serious mental illnes…
- Key Point: Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics.
- Key Point: Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018.
- Key Point: He served as a member of Karuna’s board of directors from April 2012 to March 2019.
Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of Karuna’s board of directors from April 2012 to March 2019. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner, and served as Chief Operating Officer of Tal Medical, and the acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.
Dr. Miller received his bachelor’s degree in Chemical Engineering from the University of Illinois with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



